Fly News Breaks for November 23, 2015
CLDX
Nov 23, 2015 | 07:51 EDT
Oppenheimer says that Phase II data from Celldex's Rintega plus bevacizumab in relapsed glioblastoma continued to show a survival benefit. The firm expects positive data from a Phase 3 trial of the drug in 2016. It keeps a $42 price target and Outperform rating on the shares.
News For CLDX From the Last 2 Days